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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by abnormal extracellular matrix (ECM)
turnover. Recently, activation of the WNT/b-catenin pathway has been associated with abnormal ECM turnover in various
chronic diseases. We determined WNT-pathway gene expression in pulmonary fibroblasts of individuals with and without
COPD and disentangled the role of b-catenin in fibroblast phenotype and function.
Methods: We assessed the expression of WNT-pathway genes and the functional role of b-catenin, using MRC-5 human
lung fibroblasts and primary pulmonary fibroblasts of individuals with and without COPD.
Results: Pulmonary fibroblasts expressed mRNA of genes required for WNT signaling. Stimulation of fibroblasts with TGF-b1,
a growth factor important in COPD pathogenesis, induced WNT-5B, FZD8, DVL3 and b-catenin mRNA expression. The
induction of WNT-5B, FZD6, FZD8 and DVL3 mRNA by TGF-b1 was higher in fibroblasts of individuals with COPD than
without COPD, whilst basal expression was similar. Accordingly, TGF-b1 activated b-catenin signaling, as shown by an
increase in transcriptionally active and total b-catenin protein expression. Furthermore, TGF-b1 induced the expression of
collagen1a1, a-sm-actin and fibronectin, which was attenuated by b-catenin specific siRNA and by pharmacological
inhibition of b-catenin, whereas the TGF-b1-induced expression of PAI-1 was not affected. The induction of transcriptionally
active b-catenin and subsequent fibronectin deposition induced by TGF-b1 were enhanced in pulmonary fibroblasts from
individuals with COPD.
Conclusions: b-catenin signaling contributes to ECM production by pulmonary fibroblasts and contributes to
myofibroblasts differentiation. WNT/b-catenin pathway expression and activation by TGF-b1 is enhanced in pulmonary
fibroblasts from individuals with COPD. This suggests an important role of the WNT/b-catenin pathway in regulating
fibroblast phenotype and function in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by progressive airflow limitation, which is associated with an
abnormal inflammatory response of the lungs to noxious particles
or gases. Long-term exposure to cigarette smoke is the major risk
factor for the development of COPD [1,2]. Progressive loss of lung
function can be caused by airway wall remodeling, bronchocon-
striction, occlusion of the airway lumen by mucus and destruction
of alveolar attachments of the airways within the lung (emphyse-
ma) [3]. Aberrant extracellular matrix (ECM) turnover contributes
to both airway remodeling and pulmonary emphysema.
Fibroblasts play an important role in ECM turnover in the
parenchyma and small airways by producing ECM constituents
[4–6]. Transforming growth factor-b (TGF-b) is locally upregu-
lated in COPD and is the key mediator stimulating ECM
production by recruiting and activating fibroblasts and initiating
their differentiation process into myofibroblasts [5,7–9]. Airway
fibroblasts may thus contribute to small airways remodeling in
COPD. By contrast, in the peripheral lung with pulmonary
emphysema, there is inadequate tissue repair and associated
damage, which is perhaps due to fibroblast dysfunction [10,11].
This discrepancy may be explained by insufficient activation of
fibroblast in regions affected by emphysema to compensate for the
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patientswithpulmonaryemphysemashowanaberrantproliferation
capacity and differences in ECM synthesis [12–14]. Cigarette
smoke can also affect a number of fibroblast functions implicated in
alveolar regeneration and repair [11,15]. Consequently, extrinsic
and intrinsic dysregulation of fibroblast function in COPD along
with phenotypically distinct fibroblast populations in the airways
and parenchyma, may contribute to the development of both small
airway fibrosis and emphysema [16,17].
Recently, it was demonstrated that activation of the canonical
WNT/b-catenin signaling pathway is associated with fibroblast
activation, fibrosis and tissue repair [18,19]. b-Catenin is an
essential component of canonical WNT signaling, in which it
serves a role in activating gene transcription [20]. In the presence
of WNT-ligands, cytosolic b-catenin is stabilized, permitting it to
serve as a transcriptional co-activator. In addition, various growth
factors, including TGF-b, can activate b-catenin signaling either
directly or via autocrine WNT ligand production [19,21,22].
Stabilized (non-phosphorylated) b-catenin activates several target
genes including matrix metalloproteinases (MMP’s), growth
factors, ECM proteins and pro-inflammatory mediators and
enzymes [23–31]. The role of the WNT/b-catenin pathway in
COPD is largely unknown. However, in support of a role in tissue
repair, a recent study indicates that activation of WNT/b-catenin
signaling protects against experimental emphysema in mice [32].
In the present study, we investigated the expression of WNT-
pathway genes in human lung fibroblasts and determined the
functional role of the transcriptional co-activator b-catenin in
regulating TGF-b1-induced human lung fibroblast phenotype and
function. Furthermore, we compared the expression of WNT
pathway genes and activation of b-catenin in primary pulmonary
fibroblasts of individuals with and without COPD.
Results
Expression of genes required for functional WNT
signaling by fibroblasts
We first investigated WNT pathway gene expression in MRC-5
human lung fibroblasts. A clear mRNA signal was observed for
the majority of WNT pathway genes, but with considerable
differences in the degree of expression (Figure 1A). The WNT-
ligands WNT-5A, WNT-5B and WNT-16, the Frizzled (FZD)
receptors FZD2, FZD6 and FZD8 as well as the intracellular
signaling protein dishevelled (DVL3) and the key-effector of
canonical WNT signaling, b-catenin, were abundantly expressed
(figure 1A and 1B). This subset of specific WNT pathway genes
was selected for further studies based on their abundant expression
at baseline, on previous findings indicating the regulation of these
genes by TGF-b1 in airway smooth muscle (unpublished data), and
based on recent literature indicating the involvement of the
selected WNT ligands, FZD receptors and intracellular signaling
molecules in cellular processes relevant for fibroblasts function
[35–37]. A role for additional WNT pathway genes in fibroblast
function can, however, not be ruled out. To investigate if these
genes were also highly expressed in primary human lung
fibroblasts, we performed qRT-PCR analysis of these WNT
pathway genes in fibroblasts of individuals without COPD
(control) and compared them to the expression in MRC-5
fibroblasts, which produced similar results (figure 1B).
Recently, studies have suggested that activation of WNT
signaling plays an important role in remodeling and repair in
several organs and that it may show a cooperative interaction with
the TGF-b1/smad pathway [18,38–42]. Smad signaling is key in
TGF-b1 induced cellular responses and therefore we investigated
first the phosphorylation of smad3. MRC-5 fibroblasts were
stimulated with TGF-b1 (2 ng/ml) for various time-points resulting
in a time-dependent increase in ser423/425-smad3 phosphoryla-
tion, which was most profound at the early time-points of
1–2 hours (figure 1C).
Next, we wondered if TGF-b1 would affect the expression of
the selected WNT pathway genes in human lung fibroblasts.
Stimulation of MRC-5 human lung fibroblasts with TGF-b1
(2 ng/ml; 4 hours) altered the expression profile of specific WNT-
pathway genes (figure 1D). The expression of WNT-5B, FZD8 and
b-catenin was significantly increased in TGF-b1 treated fibroblasts
(fold-induction 1.9260.22, 3.0360.57 and 1.6660.16, respective-
ly), whereas FZD2 mRNA expression was significantly down-
regulated to 0.6360.07-fold compared with untreated fibroblasts.
The expression of WNT-5A, WNT-16, FZD6 and DVL3 was
unaltered after TGF-b1 stimulation (figure 1D). Concentration-
response curves with 0.5, 2 and 5 ng/ml of TGF-b1 show that the
expression of WNT-5B, FZD8 and b-catenin in MRC-5 fibroblasts
is concentration dependent (figure 1E).
Differential WNT pathway gene expression in primary
lung fibroblasts from individuals with and without COPD
To investigate if WNT pathway gene expression was altered in
COPD, we quantified the most abundant WNT signaling pathway
genes by qRT-PCR in primary human lung fibroblasts from
individuals with and without COPD at different stages of disease
(COPD GOLD stage II or GOLD stage IV). The clinical
characteristics of the subject groups are represented in table 1.
The individuals with COPD stage II were significantly older and
individuals with COPD stage IV had a lower body mass index
(BMI). The smoking history (i.e. smoking status and pack-years)
and gender distribution was similar in all groups.
WNT ligands. First, we determined the expression profile of
the ligands WNT-5A, WNT-5B and WNT-16. No significant
differences were observed in the basal expression of WNT-5A and
WNT-5B in fibroblasts from individuals with COPD compared to
individuals without COPD (controls), whilst WNT-16 expression
was significantly higher in individuals with COPD stage II
(figure 2A–C) In line with the MRC-5 fibroblasts, stimulation
with TGF-b1 had no effect on mRNA expression of WNT-5A
and WNT-16, but induced mRNA expression of WNT-5B.
Interestingly, WNT-5B mRNA expression in TGF-b1 treated
fibroblasts was higher in individuals with than without COPD
(figure 2B). The mRNA expression of WNT-5A and WNT-16 in
TGF-b1 treated fibroblasts was not different in individuals with or
without COPD (figures 2A and 2C).
Frizzled (FZD) receptors. Basal mRNA expression of the
FZD-receptors FZD2, FZD6, and FZD8 was similar in fibroblasts
from individuals with and without COPD, independent of GOLD
stage (figure 2D–F). In contrast to what we observed in MRC-5
cells, in fibroblasts from individuals without COPD, the expression
of the FZD2 receptors was unaltered in response to TGF-b1
(figure 2D–F). Likewise, the expression of FZD2 did not differ after
TGF-b1 stimulation in fibroblasts from individuals with COPD,
independent of GOLD stage (Figure 2D). Conversely, FZD6
mRNA expression in fibroblasts from individuals with COPD was
upregulated in the presence of TGF-b1. The total FZD6 mRNA
content was significantly higher (1.6760.18–fold) in fibroblasts
from individuals with COPD than controls after TGF-b1
stimulation (figure 2E). In addition, TGF-b1 up regulated FZD8
mRNA expression in fibroblasts from individuals with as well as
without COPD. Total FZD8 mRNA content in TGF-b1
stimulated fibroblasts was higher in individuals with either
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(figure 2F).
DVL3 and b-catenin. The mRNA expression at baseline of
b-catenin, the key effector of WNT signaling, was comparable in
fibroblasts from individuals with and without COPD, whereas the
expression of the intracellular WNT signaling protein DVL3 was
significantly higher in individuals with COPD stage II (figure 2G).
However, no differences in DVL3 mRNA expression were
observed between controls and individuals with COPD stage IV.
TGF-b1 stimulation resulted in an upregulation of both DVL3 and
b-catenin mRNA in fibroblasts from individuals with and without
COPD (figure 2G–H). After TGF-b1 stimulation, total DVL3
mRNA levels in fibroblasts from COPD patients with GOLD
stage II were significantly higher than in controls (figure 2G).
TGF-b1 induces myofibroblast differentiation and
activates b-catenin signaling
We next studied activation of the WNT effector b-catenin in
response to TGF-b1 and determined its functional role in
myofibroblast differentiation. Treatment of MRC-5 human lung
fibroblasts for 48 hours with TGF-b1 (2 ng/ml) resulted in a
significant increase in protein expression of the differentiation
markers a-sm-actin, fibronectin and MMP-2 (figure 3A). Cyto-
chemical staining for filamentous actin (F-actin) indicated that
TGF-b1 (48 hours) distinctively induced the formation of stress
fibers (F-actin) in these cells, another indication of myofibroblast
differentiation (figure 3B). Stimulation of MRC-5 fibroblasts with
0.5, 2 and 5 ng/ml of TGF- b1 for 48 hours shows that the
increase of fibronectin and a-sm-actin protein expression is
concentration-dependent (figure 3C). Interestingly, the expression
of active (unphosphorylated) b-catenin followed similar concen-
tration dependence (figure 3C). Therefore, the activation of b-
catenin in response to TGF-b1 was investigated in more detail.
Treatment of fibroblasts with TGF-b1 (2 ng/ml) resulted in a
significant, time-dependent increase in total b-catenin protein
expression after 24 hours of stimulation compared to untreated
fibroblasts (figure 4A–B). Interestingly, TGF-b1 induced an even
more pronounced increase in the expression of the transcription-
ally active (non-phosphorylated) b-catenin, with kinetics similar to
the induction of total b-catenin (figure 4C). Glycogen synthase
kinase-3 (GSK-3) is a major protein kinase involved in regulating
b-catenin cellular expression and is negatively regulated by ser9
and ser21 (ser9 of GSK-3b and ser21 of GSK-3a) phosphorylation
[43]. Therefore, the effect of TGF-b1 on GSK-3 phosphorylation
was also investigated. TGF-b1 induced a strong inhibitory ser9/21
phosphorylation of GSK-3 (figure 4A and 4D). As would be
expected, expression of the transcriptionally active (non-phos-
phorylated) b-catenin distinctively increased in the cytosolic and
nuclear compartment after TGF-b1 stimulation (figure 4E and 4F).
Interestingly, activation of b-catenin signaling preceded myofibro-
blast differentiation (figure 4G).
Functional role for b-catenin in TGF-b1-induced
myofibroblast differentiation
To determine the functional role of b-catenin in myofibroblast
differentiation, we used specific small interfering RNA (siRNA) to
silence b-catenin protein expression. After siRNA treatment, total
b-catenin expression was reduced to 5767% in fibroblasts at
baseline (figure 5A). TGF-b1 stimulation after siRNA transfection,
resulted in a significant increase in b-catenin protein expression in
the non-targeting siRNA treated fibroblasts (control) (figure 5A–B),
Table 1. Clinical characteristics of the subjects involved in the
studies.
Subject groups
Control COPD stage II COPD stage IV
Number of subjects 75 6
Age (years) 58
(46–74)
73
(70–77)*
55
(52–59)
Body mass index
(Kg/m
2)
26.562.0
(n=4)
25.561.5
(n=5)
21.060.6
#
(n=6)
Sex
Male 4 5 4
Female 3 0 2
Smoking status
Ex-smoker 4 4 6
Current smoker 2 1 0
Non-smoker 1 0 0
Pack-years 36
(0–70)
42.5
(17.5–55)
30
(20–38)
FEV1 % predicted 96.9
(75.9–118.0)
52.6
(38.0–66.9)
17.1***
(14.0–18.5)
FEV1/FVC 76.0
(71.4–81.5)
49.3
(37.0–60.7)
27.7**
(14.0–62.1)
All values are represented as median values with ranges in parentheses. Ex –
smokers=not smoking for at least one year. FEV1 % predicted=Forced Expira-
tory Volume in 1 second as percentage of predicted value; FVC=Forced Vital
Capacity. Stage means severity of COPD according to GOLD criteria. Statistical
significance determined by a kruskall-wallis ANOVA followed by Dunn’s multi-
ple comparisons test or a two-way student’s t-test for unpaired observations.
*p,0.05,
**p,0.01,
***p,0.001 compared to Control group and
#p,0.05 compared to individuals with COPD stage II.
doi:10.1371/journal.pone.0025450.t001
Figure 1. Quantitative expression of specific WNT pathway genes in human lung fibroblasts. (A) WNT pathway gene expression in MRC5
human lung fibroblasts. Data shown are average Cq-values corrected for 18s ribosomal RNA expression determined in triplicate by quantitative real-
time PCR. Of note; a lower Cq-value corresponds with higher gene expression. (B) The WNT pathway genes WNT-5A, WNT-5B, WNT-16, FZD2, FZD6,
FZD8, DVL3 and b-catenin were analyzed by quantitative real-time PCR in MRC-5 fibroblasts and primary human lung fibroblasts. (C) Time-dependent
activation of smad3 in response to TGF-b1 (2 ng/ml). Phosphorylation of ser423/425-smad3 was evaluated in whole cell lysates by immunoblotting
using specific antibodies. Equal protein loading was verified by the analysis of total smad2/3. Data represents mean 6 s.e.m. of 6 independent
experiments. *p,0.05 compared to untreated MRC-5 fibroblasts determined by a two-tailed student’s t-test for paired observations. (D) qRT-PCR
analysis of WNT-5A, WNT-5B, WNT-16, FZD2, FZD6, FZD8, DVL3 and b-catenin in MRC-5 fibroblasts after 4 h of of TGF-b1 (2 ng/ml) stimulation.
Expression of WNT pathway genes by TGF-b1 is corrected for 18S rRNA and expressed relative to untreated MRC-5 fibroblasts. Data represents mean
6 s.e.m. of 5 independent experiments. *p,0.05, **p,0.01 compared to untreated MRC-5 fibroblasts determined by a two-tailed student’s t-test for
paired observations. (E) Effect of increasing concentrations TGF-b1 on WNT-5B, FZD8 and b-catenin gene expression. MRC-5 fibroblasts were
stimulated with 0.5, 2.0 and 5.0 ng/ml TGF-b1 for 24 h. WNT-5B, FZD8 and b-catenin expression was determined by qRT-PCR analysis, corrected for
18S rRNA and expressed relative to untreated MRC-5 fibroblasts (control). Data represents mean 6 s.e.m. of 4–7 independent experiments. p,0.05
for dose-dependency of WNT-5B, FZD8 and b-catenin gene expression in response to TGF-b1 determined by a One-way ANOVA.
doi:10.1371/journal.pone.0025450.g001
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transcriptionally active b-catenin was completely abrogated in
fibroblasts treated with specific siRNA against b-catenin (figure 5B).
Next, we investigated the functional effects of b-catenin
silencing on TGF-b1-induced gene and protein expression. Non-
targeting siRNA treated fibroblasts were stimulated with TGF-b1
for 24 and 48 hours (for mRNA and protein determination,
respectively), resulting in increased expression of a-sm-actin
(figure 5C and 5E) and fibronectin (figure 5D and 5F). The
induction of both a-sm-actin and fibronectin was largely
attenuated in fibroblasts treated with specific siRNA against b-
catenin (figure 5C–E). Silencing of b-catenin expression also
reduced the TGF-b1-induced collagen Ia1 mRNA expression,
whereas the expression of plasminogen activator inhibitor-1
(PAI-1) was not affected (data not shown).
To further verify the functional role of b-catenin in lung
fibroblasts we pharmacologically inhibited b-catenin signaling by
either quercetin or PKF115–584, compounds that disrupt the
interaction of the transcriptionally active b-catenin/T-cell factor-4
(TCF-4) complex [44–46]. Both pharmacological inhibitors greatly
attenuated a-sm-actin induction and fully prevented the increased
fibronectin deposition induced by TGF-b1, without affecting basal
expression of either a-sm-actin or fibronectin (figure 6A–B).
Fibroblasts of COPD patients show increased b-catenin
activation and subsequent fibronectin deposition in
response to TGF-b1
Fibroblasts from individuals with and without COPD had
similar expression of active b-catenin at baseline. Stimulation with
Figure 2. Differential WNT pathway gene expression in primary lung fibroblasts from individuals with and without COPD. Primary
lung fibroblasts were isolated from individuals without (control) and with COPD (GOLD stage II and IV) as described in the materials en methods. qRT-
PCR analysis of WNT-5A (A), WNT-5B (B), WNT-16 (C), FZD2 (D), FZD6 (E), FZD8 (F), DVL3 (G) and b-catenin (H) mRNA of primary lung fibroblasts treated
with or without TGF-b1 (2 ng/ml) for 4 h. Expression of WNT pathway genes is plotted relative to the mean expression in untreated fibroblasts from
controls. Data are derived from 7 controls and 11 COPD patients (5 GOLD stage II and 6 GOLD stage IV). mRNA expression was determined both at
baseline (open circles; #) and after TGF-b stimulation (closed circles;N). Median of each group is indicated by -----. *p,0.05, **p,0.01, ***p,0.001,
two-tailed student’s t-test for unpaired observations or a One-way ANOVA followed by a Newman-Keuls multiple comparison test.
doi:10.1371/journal.pone.0025450.g002
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in fibroblasts from individuals with and without COPD.
Interestingly, the induction of active b-catenin was significantly
higher in fibroblasts from individuals with COPD than those
without COPD (figure 7A). In accordance with the increase in
active b-catenin, fibronectin deposition was increased after TGF-
b1 stimulation and more so in fibroblasts from individuals with
COPD (figure 7B). The expression of the myofibroblast marker a-
sm-actin was also studied; however the fold induction of a-sm-
actin by TGF-b1 treatment could not be computed as basal
expression of a-sm-actin in fibroblasts was occasionally not
observed. However, no significant differences were observed for
the TGF-b1-induced a-sm-actin bands (GAPDH ratio) between
individuals with and without COPD (data not shown). Thus,
b-catenin activation and subsequent fibronectin deposition in
response to TGF-b1 is enhanced in lung fibroblasts from COPD
patients compared to lung fibroblasts from controls.
Discussion
Pulmonary fibroblasts play a pivotal role in COPD by
regulating ECM turnover in the lungs [4,11]. To our knowledge,
this is the first study demonstrating that WNT/b-catenin signaling
in pulmonary fibroblasts may play an important role in COPD.
Figure 3. TGF-b1 induces myofibroblast differentiation of MRC-5 lung fibroblasts. MRC-5 fibroblasts were grown to confluence and treated
for 24 h or 48 h with 2 ng/ml of TGF-b1. (A) Expression of the myofibroblasts markers a-sm-actin, fibronectin and MMP-2 was evaluated in whole cell
lysates by immunoblotting using specific antibodies. Equal protein loading was verified by the analysis of GAPDH. Representative immunoblots of 5–
8 independent experiments are shown. ***p,0.001, two-way student’s t-test for paired observations. (B) Evaluation of stress fiber formation in MRC-5
lung fibroblasts after TGF-b1 stimulation. MRC-5 lung fibroblasts were treated for 48 h with TGF-b1 (2 ng/ml) and subsequently fixed and
permeabilized. Cells were stained for filamentous actin (488 phalloidin; green) and nucleus (Hoechst 3342; blue). Pictures were taken at 4006
magnification. (C) Effect of increasing concentrations TGF-b1 on myofibroblast differentiation. MRC-5 fibroblasts were stimulated with 0.5, 2.0 and
5.0 ng/ml TGF-b1 for 48 h. Expression of a-sm-actin, fibronectin and active b-catenin was evaluated in whole cell lysates by immunoblotting using
specific antibodies. Equal protein loading was verified by the analysis of GAPDH. Representative immunoblots of 4 independent experiments are
shown.
doi:10.1371/journal.pone.0025450.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25450We show that pulmonary fibroblasts express genes required for
functional WNT signaling, of which WNT-5B, FZD8, DVL3 and
b-catenin were significantly induced by TGF-b1 in a concentration
dependent manner in both MRC-5 and primary human lung
fibroblasts. Interestingly, WNT-5B, FZD6 and FZD8 expression
were significantly more upregulated in response to TGF-b1 in
primary fibroblasts from individuals with than without COPD.
Furthermore, we also show that b-catenin, the key effector of
canonical WNT signaling, regulates the induction of collagen1a1,
a-sm-actin and fibronectin deposition by pulmonary fibroblasts in
response to TGF-b1, whereas the expression of PAI-1 is not
regulated by b-catenin. Finally, we provide evidence that the
induction of transcriptionally active b-catenin and subsequent
fibronectin deposition induced by TGF-b1 are significantly
enhanced in lung fibroblasts from COPD patients.
An active and complex remodeling process is present in the
peripheral lung when COPD develops, resulting in small airway
fibrosis and a variable degree of emphysema. Fibroblasts are the
primary cell type responsible for the production and maintenance
of the extracellular matrix. Alterations in fibroblast function may
therefore play an important role in COPD. In this respect, the
canonical WNT/b-catenin signaling pathway is of particular
interest, since this pathway has been linked to tissue repair and
remodeling [20,47]. Indeed, activation of canonical WNT/b-
catenin signaling attenuates experimental emphysema in mice
[32]. In that study, WNT pathway gene expression in lung tissue
of COPD patients was also examined and, although the gene
expression of specific WNT ligands and FZD receptors showed no
notable changes in whole lung homogenate, alveolar type II cells
had reduced b-catenin expression [32]. Our observations suggest
that fibroblasts from the peripheral lung are more prone to TGF-
b1 stimulation in activating WNT signaling and regulating
transcription of tissue repair genes such as fibronectin, despite
the fact that the peripheral lung is the primary site of tissue
destruction associated with pulmonary emphysema [2]. We also
demonstrate that WNT-16 and DVL3 expression is higher at
baseline in fibroblasts of individuals with COPD stage II, although
curiously this did not result in increased baseline expression of
either total or active b-catenin. Of interest is that this intrinsic
difference in WNT pathway activation was seen for fibroblasts
from both GOLD stage II and IV COPD patients compared to
fibroblasts from controls.
We propose that during COPD pathogenesis, irrespective of
GOLD stage, fibroblasts from the peripheral lung are promoted to
repair tissue damage, but that this repair response becomes
insufficient in more advanced stages of disease. This can either be
because of the development of intrinsic defects in the lung
fibroblast (e.g. reduced proliferative capacity of fibroblasts in
advanced stages of COPD [12] or altered intracellular Smad
signaling [10]) or because of aberrant activation of fibroblasts by
the locally expressed (pro-inflammatory) cytokines in the lung
and / or the presence of cigarette smoke [5,11,48]. As a result, the
destructive response in the lung may proceed and the tissue repair
response by fibroblasts is deviant and not adequate. In line with
this hypothesis the relative production of the proteoglycan versican
as well as the expression of the pro-inflammatory enzyme
cyclooxygenase-2 (COX-2), both direct targets of WNT/b-catenin
signaling [29,49,50], are higher in parenchymal fibroblasts from
COPD patients than controls [15,17]. Furthermore, versican
expression is increased in pulmonary alveolar parenchyma of mild
to moderate emphysematous COPD patients and is negatively
correlated with FEV1 [51]. These findings suggest that in COPD,
parenchymal fibroblasts may have activated canonical WNT
signaling, also in regions affected by emphysema, which regulates
the subsequent synthesis of specific ECM components and
enzymes.
The smoking histories (pack-years and smoking status) of the
individuals with and without COPD were very similar, thus
excluding that the observed differences between COPD and
controls were primarily due to differences in smoking habits. No
separate non-smoking control group (never smokers) was included
in the study design. Therefore, this study does not provide insight
into the effect of smoking on WNT pathway gene expression by
fibroblasts. There is a statistically significant difference in age
between individuals with COPD stage II (older) and individuals
with either COPD stage IV or no COPD. Since the baseline
expression of WNT pathway genes is higher in fibroblasts from
COPD stage II compared to the other two groups (significant for
WNT-16 and DVL3), we investigated the correlation between
WNT pathway gene expression and age in the individuals without
COPD (figure S2). We did not observe any significant correlation
between age and WNT pathway gene expression, implying that
these differences in gene expression at baseline are not primarily
due to age.
Tissue repair by fibroblasts is a complex process involving the
interplay of various growth factors and intracellular signaling
pathways. Recently, crosstalk between WNT signaling pathway
and growth factors in fibroblasts has been demonstrated [19,52].
For instance, the WNT ligands WNT-3A and WNT-10B activate
b-catenin signaling in NIH 3T3 fibroblasts resulting in an
increased mRNA expression of connective tissue growth factor
(CTGF, CCN2), endothelin-1 and TGF-b [53]. Moreover, the
expression of WNT1-inducible signaling protein-1 (WISP-1), a
member of the CCN family of secreted cysteine-rich matricellular
proteins and a direct target gene of WNT signaling, is increased in
patients with idiopathic pulmonary fibrosis (IPF) and contributes
to disease pathogenesis [41]. In dermal fibroblasts, both EGF
and TGF-b increased b-catenin protein stability and induced
Figure 4. Treatment with TGF-b1 increases b-catenin signaling in MRC-5 lung fibroblasts. MRC-5 fibroblasts were grown to confluence and
treated for up to 24 h with TGF-b1 (2 ng/ml). (A) Expression of total b-catenin, active (non-phosphorylated) b-catenin and ser9/21 phosphorylation of
GSK-3 were evaluated by immunoblotting using specific antibodies. Equal protein loading was verified by the analysis of GAPDH or total GSK-3,
respectively. Responses of TGF-b1 on total and active b-catenin expression (B and C) and ser9/21-GSK-3 phosphorylation (D) were quantified by
densitometry, representing mean 6 s.e.m. of 3 independent experiments. *p,0.05, ***p,0.001, two-tailed student’s t-test for paired observations or
repeated measures ANOVA followed by a Newman-Keuls multiple comparison test. (E) Evaluation of cellular localization of active (non-
phosphorylated) b-catenin in MRC-5 lung fibroblasts stimulated with TGF-b1 (2 ng/ml) for 48 h. Fixed and permeabilized MRC-5 fibroblasts were
(immuno)cytochemically stained for active (non-phosphorylated) b-catenin (Cy3; red) and stained for filamentous actin (488 phalloidin; green) and
nucleus (Hoechst 33342; blue). Pictures were taken at 4006magnification. (F) Increased cytosolic and nuclear expression of b-catenin in response to
TGF-b1 stimulation. MRC-5 fibroblasts were stimulated with TGF-b1 (2 ng/ml) for 24 h. Subsequently cytosolic and nuclear extracts were prepared.
Expression of total and active (non-phosphorylated) b-catenin was evaluated by immunoblotting. Equal protein loading was verified by the analysis
of GAPDH and Lamin A/C, respectively. Representative immunoblots of 4 independent experiments are shown. (G) b-Catenin activation precedes
myofibroblast differentiation. Expression of active b-catenin protein (open circles; #), a-sm-actin mRNA (grey triangles; .) and a-sm-actin protein
(black triangles; m) in response to TGF-b1 (2 ng/ml) was determined by immunoblotting and quantitative real time PCR. Data represents mean 6
s.e.m. of 3–8 independent experiments.
doi:10.1371/journal.pone.0025450.g004
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Current literature is limited concerning the signaling pathways
involved in the regulation of WNT pathway gene expression by
TGF-b. However, recently it was suggested that WNT gene
expression may be regulated by smad proteins, as dickkopf (DKK)
and casein kinase 1 (CSNK1A1) were predicted smad targets
genes [54]. In the present study, we show that specific WNT genes
are upregulated after 4 hours of TGF-b1 treatment, which
corresponds with the kinetics of activation of smad3. In addition,
other signaling pathways such as ERK1/2 may be activated by
TGF-b1 that regulate the WNT pathway gene expression as
demonstrated for b-catenin in our recent report [55]. Clearly,
future studies are required to characterize the regulation of WNT
pathway gene expression by TGF-b1 in more detail, as we report
that TGF-b1 induces WNT and FZD mRNA expression in human
lung fibroblasts and activates b-catenin signaling, which contrib-
utes to the fibroblast phenotype and function.
Our data suggest that TGF-b1 induces b-catenin expression via
several intracellular mechanisms. b-Catenin levels are tightly
regulated by the constitutively active enzyme GSK-3. A fraction of
cellular GSK-3 forms a complex with AXIN, casein kinase I (CK-
I) and adenomatous polyposis coli (APC); this complex phosphor-
ylates and subsequently targets b-catenin for proteosomal
degradation [20]. The activity of both GSK-3 isoforms (e.g.
GSK-3a and GSK-3b) is negatively regulated by serine (ser9 and
ser21 of GSK-3b and GSK-3a, respectively) phosphorylation,
which can be induced by numerous stimuli, including growth
factors [21,43,55,56]. We demonstrate that TGF-b1 induces a
transient time-dependent phosphorylation of both GSK-3 isoforms
in MRC-5 fibroblasts, which might account for the initial increase
of b-catenin stability. In addition, enhanced secretion of canonical
WNT ligands by fibroblasts in response to TGF-b1 may signal in
an autocrine fashion, which then stabilizes b-catenin by disrupting
the GSK-3/AXIN/CK-I/APC complex [20]. The increase in b-
catenin protein expression after TGF-b1 stimulation progresses
even when GSK-3 phosphorylation has returned to basal levels,
supporting such an autocrine signaling loop. In addition, b-catenin
protein expression can be induced by growth factors by de novo
Figure 5. Silencing b-catenin expression by specific siRNA attenuates TGF-b1-induced a-sm-actin and fibronectin expression.
Subconfluent MRC-5 lung fibroblast cultures were transfected with a siRNA against the b-catenin transcript. Control cultures were transfected with a
non-targeting control siRNA. Transfected cells were treated with TGF-b1 (2 ng/ml) for 48 h. (A–B) The efficiency of b-catenin silencing was evaluated
by immunoblotting the expression of (A) total b-catenin and (B) active b-catenin and GAPDH to correct for differences in protein loading. Data
represent mean 6 s.e.m. of 4–6 experiments. *p,0.05, **p,0.01 and ***p,0.001 compared to non-targeting siRNA control,
###p,0.001 compared
to non-targeting siRNA treated with TGF-b1 determined by a one-way ANOVA followed by a Newman-Keuls multiple comparison test. (C–F) b-catenin
siRNA attenuated TGF-b1-induced a-sm-actin (C and E) and fibronectin (D and F) gene and protein expression. Expression or mRNA was determined
by real-time PCR and normalized to 18S ribosomal mRNA expression. Protein expression was determined by immunoblotting and equal protein
loading was verified by the analysis of GAPDH. Responses were quantified and normalized to the expression of 18S rRNA (gene) or GAPDH (protein).
Data represent mean 6 s.e.m. of 5–6 independent experiments. *p,0.05, ***p,0.001 compared to non-targeting siRNA control,
#p,0.05,
##p,0.01
###p,0.001 compared to non-targeting siRNA treated with TGF-b1,
{{p,0.01 compared to b-catenin siRNA control, one-way ANOVA followed by a
Newman-Keuls multiple comparison test.
doi:10.1371/journal.pone.0025450.g005
Figure 6. Pharmacological inhibition of b-catenin attenuates TGF-b1-induced a-sm-actin and fibronectin expression. Pharmacological
inhibition of b-catenin/TCF4 signaling by quercetin or PKF115–584. Confluent MRC-5 lung fibroblasts were treated with TGF-b1 (2 ng/ml) for 48 h in
the absence or presence of either quercetin (40 mM) or PKF115–584 (100 nM). Expression of a-sm-actin (A) and fibronectin (B) was evaluated by
immunoblotting using a specific antibody. Responses were quantified by densitometry and normalized to the expression of GAPDH. Data represent
mean 6 s.e.m. of 3 independent experiments. ***p,0.001 compared untreated MRC-5 lung fibroblasts (control),
##p,0.01;
###p,0.001 to TGF-b1
treated MRC-5 lung fibroblasts determined by a one-way ANOVA followed by a Newman-Keuls multiple comparison test.
doi:10.1371/journal.pone.0025450.g006
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which TGF-b1 induces b-catenin expression in pulmonary
fibroblasts are therefore not fully understood and require further
exploration.
Surprisingly, TGF-b1 did not or only modestly affect the mRNA
expression of the canonical WNT target genes dickkopf-1 (DKK-
1), vascular endothelial growth factor (VEGF), interleukin-8 (IL-8)
or MMP-2, and attenuated AXIN-2 mRNA expression in MRC-5
fibroblasts (figure S3), even though nuclear b-catenin was clearly
induced. Thus, b-catenin contributes to the transcriptional activity
induced by TGF-b1, but this transcriptional activity may be
different from that induced by canonical WNT ligands. Indeed,
WNT-3A activates b-catenin signaling in fibroblasts but does not
or very modestly activate the transcription of collagen-1 and a-sm-
actin, whereas it potentiates the effect of TGF-b on these
myofibroblasts markers [57,58]. This implies that the interaction
between TGF-b1/smad and WNT/b-catenin signaling directs
transcription to specific genes, which may be different from those
activated by canonical WNT stimulation alone. In support, it was
recently demonstrated smad proteins and b-catenin can directly
interact, thereby (synergistically) activating the transcription of
specific genes [27,57]. Thus, further exploration of crosstalk
between growth factors, in particular TGF-b1, and the WNT-
signaling pathway in lung fibroblasts is of major interest to
understand tissue repair mechanisms.
Our results further show that TGF-b1 induced collagen Ia1 and
PAI-1 mRNA as well as a-sm-actin and fibronectin protein
expression, indicative of fibroblast activation [59]. This activation
of fibroblasts was accompanied by an increased expression of
transcriptionally active b-catenin, which was primarily present in
the nuclei of the fibroblasts. Silencing of b-catenin as well as
pharmacological inhibition of b-catenin by either quercetin or
PKF115-584, compounds that interrupt the b-catenin/TCF4
interaction [44–46], greatly attenuated the TGF-b1-induced
collagen Ia1, a-sm-actin and fibronectin expression. However,
the induction of PAI-1 did not change, indicating that b-catenin
directs TGF-b1 signaling to specific intracellular pathways.
Further, these data indicate that the responsiveness of the
fibroblasts to TGF-b1 was not affected by down regulation of b-
catenin. Collectively, these data demonstrate that b-catenin
signaling plays an important role in the activation process of
pulmonary fibroblasts. This may contribute to COPD pathogen-
esis, because the activation of b-catenin signaling and subsequent
fibronectin deposition in response to TGF-b1 is higher in lung
fibroblasts from patients with than without COPD.
In conclusion, our results indicate that the WNT/b-catenin
signaling pathway is activated in pulmonary fibroblasts in response
to the cytokine TGF-b1. In primary fibroblasts of COPD patients,
this activation is greatly enhanced compared to healthy controls,
as is the induction of b-catenin. This suggests that WNT/b-
catenin signaling plays an important role in tissue repair in the
lung, and that targeting b-catenin-dependent gene transcription
holds promise as a therapeutic intervention in COPD.
Materials and Methods
Ethics statement
The study protocol was consistent with the Research Code of
the University Medical Center Groningen (http://www.rug.nl/
umcg/onderzoek/researchcode/index) and national ethical and
professional guidelines (‘‘Code of conduct; Dutch federation of
biomedical scientific societies’’; htttp://www.federa.org).
Figure 7. Increased b-catenin activation and fibronectin deposition in fibroblast of individuals with COPD in response to TGF-b1.
Primary lung fibroblasts were isolated from individuals without (control) and with COPD (GOLD stage II and IV) as described in the materials en
methods. The fibroblasts were grown to confluence and treated for 48 h with TGF-b1 (2 ng/ml). Expression of active b-catenin (A) and fibronectin (B)
was evaluated by immunoblotting. Equal protein loading was verified by the analysis of GAPDH. Responses were quantified by densitometry and
normalized to the expression of GAPDH. Data are derived from 5 controls and 9 COPD patients (4 GOLD stage II and 5 GOLD stage IV). Median of each
group is indicated by -----. *P,0.05. Statistical differences between control and COPD were determined a two-tailed Mann-whitney test.
doi:10.1371/journal.pone.0025450.g007
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Primary lung fibroblasts were cultured from lung tissue obtained
from 18 individuals with and without COPD. Classification of
COPD severity was based on the Global initiative for chronic
obstructive lung disease (GOLD) criteria [1]. Fibroblasts obtained
from these individuals, were divided into three categories:
fibroblasts from individuals with moderate (GOLD stage II,
n=5), and severe COPD (stage IV, n=6), and from individuals
with histologically normal lungs (n=7). Emphysema was assessed
by routine histological examination of lung tissue, which was
performed by an experienced pulmonary pathologist (WT).
Fibroblasts were isolated from peripheral lung tissue of which
areas with no macroscopically visible airways and blood vessels
were used. Clinical characteristics of the groups are presented in
table 1.
Tissue from the control group (median forced expiratory
volume in one second (FEV1) 96.9% predicted) was derived from
noninvolved lung tissue of patients undergoing surgical resection
for pulmonary carcinoma. Patients had no airway obstruction and
no chronic airway symptoms, such as cough and sputum
production. Material was always taken as far away as possible
from the tumour, or from a noninvolved lobe. No histopatholog-
ical lesions were present.
Tissue of GOLD stage II COPD patients (median FEV1 52.6%
of predicted) was derived from noninvolved lung tissue from
patients undergoing resection surgery for pulmonary carcinoma.
Histopathologically emphysematous lesions were present, howev-
er, of limited and varying severity. Moderate forms of emphysema
can be histopathologically demonstrated by finding isolated or
free-lying segments of viable alveolar septal tissue or isolated cross
sections of pulmonary vessels.
Tissue of GOLD stage IV COPD patients (median FEV1 17.1%
predicted) was obtained from patients with COPD undergoing
surgery for lung transplantation or lung volume reduction. All
individuals had quitted smoking for at least 1 year before surgery.
The resected tissue showed both macroscopically and microscop-
ically severe emphysematous lesions, often accompanied by bullae.
Subpleural fibrous areas were avoided.
Pulmonary fibroblast cultures were established from parenchy-
mal lung tissue by means of an explant technique. Absence of
mycoplasma contamination in the fibroblast cultures was con-
firmed with a mycoplasma detection kit (Roche Diagnostics,
Almere, The Netherlands). Isolated cells were characterized as
fibroblasts by morphological appearance and expression pattern of
specific proteins [12]. All cells exhibited a characteristic staining
pattern for vimentin, fibronectin, and the fibroblast marker prolyl-
4-hydroxylase and lacked immunoreactivity for keratin. Five
percent or less of the cells was positive for desmin and a-sm-actin.
Cell culture
MRC-5 lung fibroblasts [33] (ATCC CCL 171) and primary
lung fibroblasts from individuals with and without COPD, were
cultured in Ham’s F12 medium supplemented with 10% (v/v)
foetal bovine serum (FBS), 2 mM L-glutamine, 100 mg/l strepto-
mycin and 100 U/ml penicillin. Unless otherwise specified, for
each experiment cells were grown to confluence and subsequently
culture medium was substituted with Ham’s F12 medium
supplemented with 0.5% (v/v) FBS, 2 mM L-glutamine,
100 mg/l streptomycin and 100 U/ml penicillin for a period of
24 hours. Cells were stimulated for different time-points with
TGF-b1 in Ham’s F12 medium supplemented with 0.5% FBS,
L-glutamine and antibiotics. When applied, pharmacological
inhibitors (i.e. quercetin 40 mM or PKF115–584 100 nM) were
added 30 minutes before the addition of TGF-b1.
mRNA isolation and real-time PCR analysis
Total mRNA was extracted using the RNeasy mini kit (Qiagen,
Venlo, The Netherlands). Briefly, cells were harvested in RNAlater
stabilization buffer and homogenized by passing the lysate 10
times through a 20 gauge needle. Lysates were then mixed with an
equal volume of 70% ethanol, and total mRNA was purified using
RNeasy mini spin columns. The eluted mRNA was quantified
using spectrophotometry (Nanodrop, ThermoScientific, Wilming-
ton, USA). Equal amounts of total mRNA (1 mg) were then reverse
transcribed and stored at -20uC until further use.
cDNA was subjected to real-time PCR, which was performed
with a MyiQ
TM Single-Color detection system (Bio-Rad labora-
tories Inc. Life Science group, Hercules, CA, USA). In short,
12.5 mli Q
TM SYBR Green Supermix, containing fluorescein to
account for well to well variation, 0.1 mM of gene-specific forward
and reverse primer and 1 ml of 1:5 diluted cDNA sample were
used in a total volume of 25 ml and added to a 96 well plate. The
sequences of the primers used for determining WNT pathway
components and WNT target genes are listed in the supporting
information tables (table S1, S2, S3, S4).
Real-time PCR data were analyzed using the comparative
cycle threshold (Cq: amplification cycle number) method. Cycle
parameters were: denaturation at 94uC for 30 seconds, annealing at
60uC for 30 seconds, and extension at 72uC for 30 seconds for 40
cycles followed by 5 minutes at 72uC. The amount of target gene
was normalized to the endogenous reference gene 18S ribosomal
RNA (Cqgene of interest –C q 18S rRNA;d e s i g n a t e da sDCq). Several
housekeeping genes, including b2-microglobulin (B2M; NM_00408)
and phospholipase A2 (YWAHZ; NM_003406), were tested for the
influence of the experimental procedure on the expression [34]. The
expression of both ribosomal protein S18 (18S rRNA) and b2-
microglobulin was stable in the tested conditions. Phospholipase A2
(YWAHZ; NM_003406) expression fluctuated after TGF-b stimu-
lation, however. Ribosomal protein S18 was chosen as most optimal
householdgene because gene expression was moststableunder basal
as well as stimulation conditions (figure S1). Relative differences in
gene expression were determined using the equation 2
2(DDCq).
siRNA transfection
MRC-5 fibroblasts were grown to ,90% confluence in 6-well
cluster plates and transiently transfected with a 21-bp, double-
stranded siRNA targeted against the b-catenin transcript (Qiagen,
Venlo, The Netherlands). Cells were transfected in serum-free
Ham’s F12 without any supplements using 1.5 mg/ml of siRNA
in combination with lipofectamine 2000 transfection reagent.
Control transfections were performed using a non-silencing control
siRNA (Qiagen, Venlo, The Netherlands). After 6 hours of
transfection, cells were washed once with warm (37uC) Hank’s
Balanced Salt Solution (HBSS; composition [mg/l]: KCl 400,
KH2PO4 60, NaCl 8000, NaHCO3 350, Na2HPO4.1H2O5 0 ,
glucose 1000, pH: 7.4) followed by a period of 24 hours in Ham’s
F12 supplemented with 0.5% FBS, L-glutamine and antibiotics.
Consecutively, medium was refreshed and cells were stimulated
with TGF-b1 (2 ng/ml) for 48 hours.
Preparation of cell lysates
To obtain whole cell lysates, cells were washed once with ice-
cold (4uC) HBSS then lysed in ice-cold sodiumdodecylsulphate
(SDS) buffer (composition: 62.5 mM Tris, 2% w/v SDS, 1 mM
NaF, 1 mM Na3VO4,1 0mg/ml aprotinin, 10 mg/ml leupeptin,
7 mg/ml pepstatin A, pH 6.8). Lysates were then sonicated and
protein concentration was determined according to Pierce protein
determination according to the manufacturer’s instructions.
Lysates were stored at 220uC till further use.
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Confluent MRC-5 fibroblasts were serum deprived in Ham’s
F12 medium supplemented with 0.5% (v/v) FBS, 2 mM L-
glutamine, 100 mg/l streptomycin and 100 U/ml penicillin for a
period of 24 hours. Subsequently cells were stimulated for 24 hour
with TGF-b1 (2 ng/ml) and nuclear extracts were prepared using
the nuclear extract kit (40010, Active Motif) according to the
manufacturer’s instructions. Protein concentration in the nuclear
extracts was determined according to the Bradford protein assay.
Nuclear extracts were stored at 280uC till further use.
Western blot analysis
Equal amounts of protein (10–20 mg/lane) were subjected to
electrophoresis on polyacrylamide gels, transferred to nitrocellu-
lose membranes and analyzed for the proteins of interest using
specific primary and HRP-conjugated secondary antibodies. By
using enhanced chemiluminescence reagents, bands were either
subsequently visualized on film or recorded in the G:BOX iChemi
gel documentation system equipped with GeneSnap image
acquisistion software (Syngene; Cambridge; UK). Band intensities
were quantified by densitometry using Totallab
TM software
(Nonlinear dynamics; Newcastle, UK) or GeneTools analysis
software (Syngene; Cambridge; UK), respectively.
Immunocytochemistry
Lung fibroblasts were plated onto Lab-Tek
TM borosilicate
chamber slides and treated with TGF-b1 2 ng/ml for 48 hours,
fixed for 15 min at 4uC in cytoskeletal (CB) buffer (10 mM MES,
150 mM NaCl, 5 mM EGTA, 5 mM MgCl2 and 5 mM glucose at
pH 6.1) containing 3% paraformaldehyde (PFA). Cells were then
permeabilized by incubation for 5 min at 4uC in CB buffer
containing 3% PFA and 0.3% Triton X-100. For immunofluores-
cence microscopy, fixed cells were first blocked for 2 hours at room
temperature in Cyto-TBS buffer (20 mM Tris base, 154 mM NaCl,
2.0 mM EGTA and 2.0 mM MgCl2 at pH 7.2) containing 1%
bovine serum albumin (BSA) and 2% normal donkey serum.
Incubation with primary antibody (i.e unphosphorylated-b-catenin,
diluted 1:200) occurred overnight at 4uC in Cyto-TBS containing
0.1% Tween 20 (Cyto-TBST). Incubation with Cy3-conjugated
secondary antibody was for 2 h at room temperature in Cyto-
TBST. Filamentous actin was stained with Alexa Fluor 488
phalloidin (15 minutes at RT) and nuclei with Hoechst 3342. After
staining, coverslips were mounted using ProLong Gold antifade
reagent (Invitrogen) and analyzed by using an Olympus AX70
microscope equipped with digital image capture system (ColorView
Soft System with Olympus U CMAD2 lens).
Antibodies and reagents
Mouse anti-a-sm-actin, horseradish peroxidase (HRP)-conjugated
goat anti-mouse antibody, HRP-conjugated goat anti-rabbit anti-
body and HRP-conjugatedrabbitanti-goat antibodywere purchased
from Sigma (St. Louis, MO, USA). Goat anti-MMP-2 antibody was
purchased from R&D systems (Minneapolis, MN, USA). Rabbit
anti-GSK-3 antibody, goat anti-fibronectin (C20) antibody, Mouse
anti-Lamin A/C antibody, mouse anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibody and Rabbit-anti-Smad2/3
antibody were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Rabbit anti-phospho-Ser9/21-GSK-3 antibody
and rabbit anti-phospho-432/425-smad3 antibody were from Cell
Signaling Technology (Beverly, MA, USA). Mouse anti-total
b-catenin antibody was from BD Biosciences (San Jose, CA, USA).
Mouse anti-non-phosphorylated-b-catenin antibody (clone 8E7) was
from Millipore (Amsterdam, the Netherlands). Cy3 conjugated
secondary antibodies were obtained from Jackson Immunoresearch
(West Grove, PA, USA). Lipofectamine 2000 transfection reagent
and alexa Fluor 488 phalloidin were from Invitrogen (Paisley, UK).
Recombinant human TGF-b1 was from R&D systems (Abingdon,
UK). All other chemicals were of analytical grade.
Supporting Information
Figure S1 18S ribosomal RNA abundance in primary
fibroblasts individuals without and with COPD. Primary
lung fibroblasts were isolated from individuals without (control)
and with COPD (GOLD stage II and IV) as described in the
methods. The fibroblasts were grown to confluence and treated for
4 hours with TGF-b1 (2 ng/ml). Analysis of 18S ribosomal RNA is
performed by qRT-PCR analysis with 0.025 mg of cDNA as input.
(A) Average 18S rRNA expression in primary human lung
fibroblasts and (B) raw Cq-values for all the individual subjects.
18S rRNA expression at baseline is indicated by open circles (#)
and after TGF-b1 stimulation (2 ng/ml; 4 h) by closed circles (N).
Median of each group is indicated by -----.
(TIF)
Figure S2 No age-dependent effects on WNT pathway
gene expression in pulmonary fibroblasts of individuals
without COPD. Expression of WNT-5B, DVL3 and FZD8 as a
function of age of the individual primary lung fibroblasts isolated
from individuals without COPD (control) as described in the
methods. The fibroblasts were grown to confluence and subse-
quently mRNA was isolated. Analysis of WNT pathway gene
expression is performed by qRT-PCR and corrected for 18S rRNA
expression. The uninterrupted line indicates the linear regression.
(TIF)
Figure S3 Effect of TGF-b stimulation on canonical
WNT target genes in human lung fibroblasts. qRT-PCR
analysis of a-sm-actin (positive control), AXIN-2, vascular
endothelial growth factor (VEGF), dickkopf-1 (DKK-1), interleu-
kin-8 (IL-8) and matrix metalloproteinase-2 (MMP-2) in MRC-5
fibroblasts after 24 h of TGF-b1 (2 ng/ml) stimulation. Expression
of canonical WNT target genes by TGF-b1 is corrected for 18S
rRNA and expressed relative to untreated MRC-5 fibroblasts
(control). Data represents mean 6 s.e.m. of 5–10 independent
experiments. *p,0.05, ***p,0.001 compared to untreated MRC-
5 fibroblasts (two-tailed student’s t-test for paired observations).
(TIF)
Table S1 Primers used for determination of WNT
ligands by qRT-PCR analysis.
(DOCX)
Table S2 Primers used for determination of the dishev-
elled protein family by qRT-PCR analysis.
(DOCX)
Table S3 Primers used for determination of FZD
receptors by qRT-PCR analysis.
(DOCX)
Table S4 Primers used for determination of LRP-
coreceptors, WNT target genes and housekeeping genes
by qRT-PCR analysis.
(DOCX)
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